Contact
searchSearch
HMP Global
Login

Advertisement

ADVERTISEMENT

News

News
FDA Approves Osimertinib Following Chemoradiation for Patients With Locally Advanced, Unresectable Non-Small Cell Lung Cancer Harboring EGFR Mutations
09/25/2024
Based on results from the LAURA trial, the FDA has approved osimertinib for patients with locally advanced, unresectable non-small lung cancer harboring EGFR mutations who do not experience disease progression on or after concurrent or...
Based on results from the LAURA trial, the FDA has approved osimertinib for patients with locally advanced, unresectable non-small lung cancer harboring EGFR mutations who do not experience disease progression on or after concurrent or...
Based on results from the LAURA...
09/25/2024
Oncology
FDA Approval
FDA Grants Approval to Amivantamab With Carboplatin and Pemetrexed for Patients With NSCLC With EGFR Exon 19 Deletions or L858R Mutations
09/20/2024
The FDA approved amivantamab plus carboplatin and pemetrexed for patients with locally advanced or metastatic non-small cell lung cancer with EGFR exon 19 deletions or exon 21 L858R substitution mutations and disease progression on or...
The FDA approved amivantamab plus carboplatin and pemetrexed for patients with locally advanced or metastatic non-small cell lung cancer with EGFR exon 19 deletions or exon 21 L858R substitution mutations and disease progression on or...
The FDA approved amivantamab...
09/20/2024
Oncology
Conference Coverage
Zipalertinib Demonstrated Promising Anti-Tumor Activity Among Patients With EGFR-Mutated Non-Small Cell Lung Cancer
09/10/2024
According to results from the phase 2b REZILIENT1 study, zipalertinib demonstrated promising anti-tumor activity among patients with EGFR exon 20 insertion-mutated non-small cell lung cancer who experienced disease progression after treatment...
According to results from the phase 2b REZILIENT1 study, zipalertinib demonstrated promising anti-tumor activity among patients with EGFR exon 20 insertion-mutated non-small cell lung cancer who experienced disease progression after treatment...
According to results from the...
09/10/2024
Oncology

Advertisement

Conference Coverage
Zipalertinib Demonstrated Promising Anti-Tumor Activity Among Patients With EGFR-Mutated Non-Small Cell Lung Cancer
09/10/2024
According to results from the phase 2b REZILIENT1 study, zipalertinib demonstrated promising anti-tumor activity among patients with EGFR exon 20 insertion-mutated non-small cell lung cancer who experienced disease progression after treatment...
According to results from the phase 2b REZILIENT1 study, zipalertinib demonstrated promising anti-tumor activity among patients with EGFR exon 20 insertion-mutated non-small cell lung cancer who experienced disease progression after treatment...
According to results from the...
09/10/2024
Oncology
News
FDA Approved Lazertinib Plus Amivantamab for Advanced Non-Small Cell Lung Cancer With EGFR Mutations
08/20/2024
The FDA has approved lazertinib plus amivantamab for adult patients with locally advanced or metastatic non-small cell lung cancer with EGFR exon 19 deletions or exon 21 L858R substitution mutations.
The FDA has approved lazertinib plus amivantamab for adult patients with locally advanced or metastatic non-small cell lung cancer with EGFR exon 19 deletions or exon 21 L858R substitution mutations.
The FDA has approved lazertinib...
08/20/2024
Oncology
News
FDA Approved Lazertinib Plus Amivantamab for Advanced Non-Small Cell Lung Cancer With EGFR Mutations
08/20/2024
The FDA has approved lazertinib plus amivantamab for adult patients with locally advanced or metastatic non-small cell lung cancer with EGFR exon 19 deletions or exon 21 L858R substitution mutations.
The FDA has approved lazertinib plus amivantamab for adult patients with locally advanced or metastatic non-small cell lung cancer with EGFR exon 19 deletions or exon 21 L858R substitution mutations.
The FDA has approved lazertinib...
08/20/2024
Oncology

Advertisement

News
FDA Approved Lazertinib Plus Amivantamab for Advanced Non-Small Cell Lung Cancer With EGFR Mutations
08/20/2024
The FDA has approved lazertinib plus amivantamab for adult patients with locally advanced or metastatic non-small cell lung cancer with EGFR exon 19 deletions or exon 21 L858R substitution mutations.
The FDA has approved lazertinib plus amivantamab for adult patients with locally advanced or metastatic non-small cell lung cancer with EGFR exon 19 deletions or exon 21 L858R substitution mutations.
The FDA has approved lazertinib...
08/20/2024
Oncology
News
Osimertinib Lacks Activity in Neoadjuvant Setting for Early-Stage Non-Small Cell Lung Cancer With EGFR Mutation
08/08/2024
Results from a phase 2 study demonstrated that neoadjuvant osimertinib did not improve the major pathological response rate among patients with early-stage non-small cell lung cancer harboring an EGFR mutation.
Results from a phase 2 study demonstrated that neoadjuvant osimertinib did not improve the major pathological response rate among patients with early-stage non-small cell lung cancer harboring an EGFR mutation.
Results from a phase 2 study...
08/08/2024
Oncology
News
First-Line Amivantamab Plus Lazertinib Superior to Osimertinib Among Patients With Locally Advanced or Metastatic EGFR-Mutated Non-Small Cell Lung Cancer
07/18/2024
Results from the phase 3 MARIPOSA study found that first-line amivantamab plus lazertinib demonstrated superior efficacy compared to osimertinib among patients with locally advanced or metastatic EGFR-mutated non-small cell lung cancer.
Results from the phase 3 MARIPOSA study found that first-line amivantamab plus lazertinib demonstrated superior efficacy compared to osimertinib among patients with locally advanced or metastatic EGFR-mutated non-small cell lung cancer.
Results from the phase 3...
07/18/2024
Oncology

Advertisement

Conference Coverage
Sunvozertinib Shows Promise Among Patients With Platinum Pre-Treated Non-Small Cell Lung Cancer Harboring EGFR Mutations
06/20/2024

Stephanie Holland

Stephanie Holland
Primary analysis results from the phase 2 WU-KONG1 study found that sunvozertinib demonstrated promising anti-tumor efficacy and safety among patients with platinum pre-treated locally advanced or metastatic non-small cell lung cancer...
Primary analysis results from the phase 2 WU-KONG1 study found that sunvozertinib demonstrated promising anti-tumor efficacy and safety among patients with platinum pre-treated locally advanced or metastatic non-small cell lung cancer...
Primary analysis results from...
06/20/2024
Oncology

Advertisement

Advertisement

Advertisement

Recent News

FDA Alerts
FDA Approves Zolbetuximab Plus Chemotherapy for Patients With HER2-Negative Gastric/Gastroesophageal Junction Adenocarcinoma With CLDN18.2-Positive Tumors
10/18/2024
Based on results from the SPOTLIGHT and GLOW trials, the FDA has approved first-line zolbetuximab plus fluoropyrimidine and platinum-containing chemotherapy for patients with locally advanced, unresectable, or metastatic HER2-negative gastric...
Based on results from the SPOTLIGHT and GLOW trials, the FDA has approved first-line zolbetuximab plus fluoropyrimidine and platinum-containing chemotherapy for patients with locally advanced, unresectable, or metastatic HER2-negative gastric...
Based on results from the...
10/18/2024
Oncology
Conference Coverage
First-Line Abemaciclib Plus Endocrine Therapy Improves Efficacy Among Patients With HR-Positive, HER2-Negative Advanced Breast Cancer
10/18/2024
Results from the phase 2 ABIGAIL trial demonstrated that first-line abemaciclib plus endocrine therapy improves efficacy compared to standard chemotherapy among patients with HR-positive, HER2-negative advanced breast cancer.
Results from the phase 2 ABIGAIL trial demonstrated that first-line abemaciclib plus endocrine therapy improves efficacy compared to standard chemotherapy among patients with HR-positive, HER2-negative advanced breast cancer.
Results from the phase 2 ABIGAIL...
10/18/2024
Oncology
FDA Approval
FDA Approves Tumor Treating Fields Wearable Device for Patients With Metastatic Non-Small Cell Lung Cancer
10/17/2024
On October 15, 2024, the FDA granted approval to the Optune Lua, a wearable device that delivers Tumor Treating Fields, for treatment of patients with metastatic non-small cell lung cancer.
On October 15, 2024, the FDA granted approval to the Optune Lua, a wearable device that delivers Tumor Treating Fields, for treatment of patients with metastatic non-small cell lung cancer.
On October 15, 2024, the FDA...
10/17/2024
Oncology
News
Treatment With 131L-Apamistamab Before AlloHCT Demonstrates Efficacy, Safety Among Older Patients With R/R AML
10/15/2024
According to phase 3 results from the SIERRA trial, anti-CD45 radioconjugate 131I-apamistamab was well-tolerated and showed a higher durable complete remission rate than standard care among older patients with relapsed/refractory acute...
According to phase 3 results from the SIERRA trial, anti-CD45 radioconjugate 131I-apamistamab was well-tolerated and showed a higher durable complete remission rate than standard care among older patients with relapsed/refractory acute...
According to phase 3 results...
10/15/2024
Oncology
FDA Approval
FDA Approves Inavolisib, With Palbociclib and Fulvestrant, for Endocrine-Resistant, PIK3CA-Mutated, HR-Positive, HER2-Negative Advanced Breast Cancer
10/10/2024
The FDA has approved inavolisib, with palbociclib and fulvestrant for patients with endocrine-resistant, PIK3CA-mutated HR-positive, HER2-negative locally advanced or metastatic breast cancer.
The FDA has approved inavolisib, with palbociclib and fulvestrant for patients with endocrine-resistant, PIK3CA-mutated HR-positive, HER2-negative locally advanced or metastatic breast cancer.
The FDA has approved inavolisib,...
10/10/2024
Oncology
News
Momelotinib Demonstrates Improved Spleen and Symptom Requirements Among Subgroup of Patients With JAK Inhibitor-Naive Myelofibrosis
10/10/2024
Momelotinib was well-tolerated, improved spleen and symptom responses, and reduced transfusion burden among a subgroup of patients with JAK inhibitor-naive myelofibrosis, determined an analysis of the phase 3 SIMPLIFY-1 study.
Momelotinib was well-tolerated, improved spleen and symptom responses, and reduced transfusion burden among a subgroup of patients with JAK inhibitor-naive myelofibrosis, determined an analysis of the phase 3 SIMPLIFY-1 study.
Momelotinib was well-tolerated,...
10/10/2024
Oncology
News
Nivolumab, Pomalidomide, and Elotuzumab Combination for Patients With R/R Multiple Myeloma
10/10/2024
Nivolumab plus pomalidomide and dexamethasone plus or minus elotuzumab did not demonstrate a clinical benefit compared with pomalidomide and dexamethasone treatment for patients with relapsed/refractory multiple myeloma, according to phase 3...
Nivolumab plus pomalidomide and dexamethasone plus or minus elotuzumab did not demonstrate a clinical benefit compared with pomalidomide and dexamethasone treatment for patients with relapsed/refractory multiple myeloma, according to phase 3...
Nivolumab plus pomalidomide and...
10/10/2024
Oncology
News
Evaluating Long-Term Efficacy and Safety of AlloSCT Among Patients With Peripheral T-Cell Lymphoma
10/10/2024
While allogeneic stem cell transplantation is the preferred treatment for younger, transplant-eligible patients with relapsed/refractory peripheral T-cell lymphoma, it is currently not recommended as part of first-line consolidation,...
While allogeneic stem cell transplantation is the preferred treatment for younger, transplant-eligible patients with relapsed/refractory peripheral T-cell lymphoma, it is currently not recommended as part of first-line consolidation,...
While allogeneic stem cell...
10/10/2024
Oncology
News
Neo/Adjuvant Pembrolizumab Significantly Improves Overall Survival for Patients With Early-Stage Triple-Negative Breast Cancer
10/09/2024
According to results from the phase 3 KEYNOTE-522 trial, neoadjuvant pembrolizumab plus chemotherapy followed by adjuvant pembrolizumab significantly improved overall survival among patients with early-stage triple-negative breast cancer.
According to results from the phase 3 KEYNOTE-522 trial, neoadjuvant pembrolizumab plus chemotherapy followed by adjuvant pembrolizumab significantly improved overall survival among patients with early-stage triple-negative breast cancer.
According to results from the...
10/09/2024
Oncology
Conference Coverage
Optimal Ifinatamab Deruxtecan Dose for Patients With Heavily Pretreated Extensive-Stage Small Cell Lung Cancer
10/09/2024
According to interim analysis results from the ongoing phase 2 IDeate-Lung01 trial, 12 mg/kg of ifinatamab deruxtecan is preferable to 8 mg/kg among patients with heavily pretreated extensive-stage small cell lung cancer.
According to interim analysis results from the ongoing phase 2 IDeate-Lung01 trial, 12 mg/kg of ifinatamab deruxtecan is preferable to 8 mg/kg among patients with heavily pretreated extensive-stage small cell lung cancer.
According to interim analysis...
10/09/2024
Oncology

Advertisement

Advertisement

Advertisement

Advertisement

Advertisement

Advertisement

Advertisement

Advertisement

Advertisement

Advertisement

Advertisement

Specialties

Events

Year Round Education

HMP Global Products

HMP Education Logo
HMP Omnimedia Logo
HMP Europe Logo
© 2024 HMP Global. All Rights Reserved.
Cookie Policy Privacy Policy Term of Use